Book Excerpt from You Bet Your Life

In his book’s Introduction, physician-scientist Paul A. Offit reviews the unusual constellation of circumstances around the development of COVID-19 vaccines.

Written byPaul A. Offit
| 4 min read
pill bottle with dice spilling out

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

ABOVE: © ISTOCK.COM, GERVILLE

I first started working on this book at the beginning of one of the worst pandemics in history. On November 17, 2019, a bat coronavirus made its debut in the human population. The virus was called SARS-CoV-2 and the disease was called COVID-19 (coronavirus disease-2019). Just one year after it had arrived, the virus had infected hundreds of millions of people and killed more than a million, mostly from pneumonia. And it was just getting started.

Although this bat coronavirus was new, human coronaviruses have been around for decades. First identified in the early 1960s, human coronaviruses cause coughs, colds, sore throats, and pneumonia. At our hospital, the Children’s Hospital of Philadelphia, human coronaviruses account for about 20 percent of all respiratory infections during the winter. This bat virus, however, was different.

All of these surprises occurred within the first year of the virus’s debut. It ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies